TSP50 encodes a testis-specific protease and is negatively regulated by p53

Cancer Research

Volumn 67, Issue 3, 2007, Pages 1239-1245

  Xu, Haopeng ^a   Shan, Jidong ^b   Jurukovski, Vladimir ^a   Yuan, Liming ^c   Li, Jianhua ^c   Tian, Kegui ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Northwell Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; SERINE PROTEINASE; TESTIS SPECIFIC PROTEASE 50; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CELL MEMBRANE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOPLASM; DOWN-REGULATION; ENDOPLASMIC RETICULUM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GLUTATHIONE TRANSFERASE; HELA CELLS; HUMANS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); RECOMBINANT FUSION PROTEINS; SERINE ENDOPEPTIDASES; TRANSGENES;

EID: 33847069272     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3688     Document Type: Article

References (47)

1. Yuan L, Shan J, De Risi D, et al. Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer. Cancer Res 1999;59:3215-21.
2. Shan J, Yuan L, Xiao Q, et al. TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells. Cancer Res 2002;62:290-4.
3. Xu HP, Yuan L, Shan J, Feng H. Localization and expression of TSP50 protein in human and rodent testes. Urology 2004;64:826-32.
4. Jegou B, Sharpe RM. Paracrine mechanisms in testicular control. In: Molecular biology of the male reproductive system. New York: Academic Press; 1993. p. 271-310.
5. Eddy EM. Role of heat shock protein HSP70-2 in spermatogenesis. Rev Reprod 1999;4:23-30.
6. Beard J. The cancer problem. Lancet 1905;165:281-3.
7. Gurchot C. The trophoblast theory of cancer (John Beard, 1857-1924) revisited. Oncology 1975;31:310-33.
8. Disis ML, Cheever MA. Oncogenic proteins as tumor antigens. Curr Opin Immunol 1996;8:637-42.
9. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997;94:1914-8.
10. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
11. Scanlan MJ, Chen YT, Williamson B, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-8.
12. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-17.
13. Old LJ. Cancer/testis (CT) antigens: a new link between gametogenesis and cancer. Cancer Immun 2001;1:1.
14. Kirkin AF, Dzhandzhugazyan KN, Zeuthen J. Cancer/testis antigens: structural and immunobiological properties. Cancer Invest 2002;20:222-36.
15. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
16. Johnson RA, Ince TA, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 2001;276:27716-20.
17. Benoist C, Chambon P. In vivo sequence requirements of the SV40 early promoter region. Nature 1981;290:304-10.
18. Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 1987;51:1079-90.
19. Menon AG, Anderson KM, Riccardi VM, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A 1990;87:5435-9.
20. Cai Z, Capoulade C, Moyret-Lalle C, et al. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene 1997;15:2817-26.
21. Shan J, Mason JM, Yuan L, et al. Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells. Gene 2000;257:67-75.
22. Shan J, Yuan L, Budman DR, Xu HP. WTH3, a new member of the Rab6 gene family, and multidrug resistance. Biochim Biophys Acta 2002;1589:112-23.
23. Camps JL, Chang SM, Hsu TC, et al. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci U S A 1990;87:75-9.
24. Vayssade M, Haddada H, Faridoni-Laurens L, et al. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 2005;116:860-9.
25. Tomita Y, Marchenko N, Erster S, et al. WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 2006;281:8600-6.
26. Mason JM, Xu HP, Rao SK, et al. Lefty contributes to the remodeling of extracellular matrix by inhibition of connective tissue growth factor and collagen mRNA expression and increased proteolytic activity in a fibrosarcoma model. J Biol Chem 2002;277:407-15.
27. Strating H, Clarice AJ. Differentiation of bacterial autolysins by zymogram analysis. Anal Biochem 2001;291:149-54.
28. Tian K, Jurukovski V, Wang XP, Kaplan MH, Xu H. Epigenetic regulation of WTH3 in primary and cultured drug-resistant breast cancer cells. Cancer Res 2005;65:10024-31.
29. Tian K, Jurukovski V, Yuan L, Shan J, Xu H. WTH3, which encodes a small G protein, is differentially regulated in multidrug-resistant and sensitive MCF7 cells. Cancer Res 2005;65:7421-8.
30. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
31. Wei L, Alhenc-Gelas F, Soubrier F, Michaud A, Corvol P, Clauser E. Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem 1991;266:5540-6.
32. Inoue M, Kanbe N, Kurosawa M, Kido H. Cloning and tissue distribution of a novel serine protease esp-1 from human eosinophils. Biochem Biophys Res Commun 1998;252:307-12.
33. Hooper JD, Nicol DL, Dickinson JL, et al. Testisin, a new human serine proteinase expressed by premeiotic testicular germ cells and lost in testicular germ cell tumors. Cancer Res 1999;59:3199-205.
34. Hooper JD, Bowen N, Marshall H, et al. Localization, expression and genomic structure of the gene encoding the human serine protease testisin. Biochim Biophys Acta 2000;1492:63-71.
35. Beldent V, Michaud A, Wei L, Chauvet MT, Corvol P. Proteolytic release of human angiotensin-converting enzyme. Localization of the cleavage site. J Biol Chem 1993;268:26428-34.
36. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999;187:127-37.
37. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005;103:1551-60.
38. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49.
39. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-808.
40. Minagawa Y, Kigawa J, Itamochi H, et al. Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways. Jpn J Cancer Res 1999;90:1373-9.
41. Yamashita H, Nishio M, Fujii Y, Iwase H. Dominant-negative Stat5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice. Cancer Sci 2004;95:662-65.
42. Noel A, Simon N, Raus J, Foidart JM. Basement membrane components (Matrigel) promote the tumorigenicity of human breast adenocarcinoma MCF7 cells and provide an in vivo model to assess the responsiveness of cells to estrogen. Biochem Pharmacol 1992;43:1263-7.
43. Hackett AJ, Smith HS, Springer EL, et al. Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J Natl Cancer Inst 1977;58:1795-806.
44. Pilat MJ, Schwab ED, Yao KL, Pienta KJ. Examination of the DNA methylation properties in nontumorigenic and tumorigenic breast epithelial cell lines. Anticancer Res 1998;18:2575-82.
45. Takino T, Sato H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J Biol Chem 1995;270:23013-20.
46. Strongin AY. Mislocalization and unconventional functions of cellular MMPs in cancer. Cancer Metastasis Rev 2006;25:87-98.
47. Jane SM, Gumucio DL, Ney PA, Cunningham JM, Nienhuis AW. Methylation-enhanced binding of Sp1 to the stage selector element of the human gamma-globin gene promoter may regulate development specificity of expression. Mol Cell Biol 1993;13:3272-81.